In aged mice, cytotoxic CD4+ T cells drive the shift of blood cell production toward myeloid lineages through CCL5–CCR5 signaling, reinforcing the low-grade inflammatory state characteristic of older immune systems. Blocking that axis with maraviroc, an approved CCR5 antagonist, restored a more balanced output from the marrow. The work identifies a specific, druggable lymphocyte–stem cell interaction behind age-related immune decline.
Key Points
- Cytotoxic CD4+ T cells push aged marrow toward myeloid-biased output
- CCL5–CCR5 signaling mediates the shift and sustains inflammation
- Maraviroc, an approved CCR5 antagonist, rebalanced immunity in aged mice
Longevity Analysis
Age-related inflammation is often treated as diffuse background noise, yet here it traces to a defined cellular conversation between T cells and hematopoietic progenitors that can be interrupted. Correctly attributing the source of an inflammatory signal — rather than suppressing its downstream effects — determines whether an intervention restores marrow output or merely blunts symptoms. An existing, well-characterized drug acting on this pathway shortens the distance between mechanistic insight and testable protocol, though the evidence remains preclinical and human translation is unestablished.
Original published by Nature Aging.